Mural Oncology Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Mural Oncology.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 24.0% |
Revenue growth rate | n/a |
Future return on equity | -116.5% |
Analyst coverage | Low |
Last updated | 04 Apr 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 26 | N/A | N/A | N/A | 1 |
12/31/2023 | N/A | -207 | -198 | -194 | N/A |
9/30/2023 | N/A | -196 | -192 | -189 | N/A |
6/30/2023 | N/A | -196 | -180 | -176 | N/A |
3/31/2023 | N/A | -193 | -177 | -172 | N/A |
12/31/2022 | N/A | -190 | -174 | -169 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MURA's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if MURA's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if MURA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if MURA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if MURA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MURA is forecast to be unprofitable in 3 years.